Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last kr44.10 SEK
Change Today +0.10 / 0.23%
Volume 93.3K
CEVI On Other Exchanges
Symbol
Exchange
Stockholm
Berlin
OTC US
As of 9:12 AM 06/30/15 All times are local (Market data is delayed by at least 15 minutes).

cellavision ab (CEVI) Snapshot

Open
kr43.50
Previous Close
kr44.00
Day High
kr44.60
Day Low
kr42.30
52 Week High
04/7/15 - kr56.00
52 Week Low
06/30/14 - kr22.40
Market Cap
1.1B
Average Volume 10 Days
135.6K
EPS TTM
kr1.32
Shares Outstanding
23.9M
EX-Date
05/7/15
P/E TM
33.4x
Dividend
kr1.00
Dividend Yield
2.26%
Current Stock Chart for CELLAVISION AB (CEVI)

Related News

No related news articles were found.

cellavision ab (CEVI) Related Businessweek News

No Related Businessweek News Found

cellavision ab (CEVI) Details

CellaVision AB (publ) develops and sells systems for routine analysis of blood and other body fluids in health care services sector. The company offers analyzers, supplementary software, and peripheral equipment for digital microscopy in the sub-field of hematology. It provides CellaVision DM9600 and CellaVision DM1200, which automatically perform a preliminary differential count on peripheral blood or body fluid smears, as well as pre-classify the white blood cells, pre-characterize parts of the red morphology, and offer functionality for platelet estimation; DI-60, an automated blood analysis line; and CellaVision DM9600 Vet and CellaVision DM1200 Vet for blood analysis at veterinary laboratories. The company’s products comprise CellaVision Body Fluid Application for analyzing body fluids, including cerebrospinal, pleural and synovial fluids; CellaVision Remote Review Software Citrix Ready that enables remote users to access analyzed slides, and reclassify cells and sign slides from another location; CellaVision Proficiency Software, a Web-based program for testing of blood and body fluid differentials; CellaVision Image Capture System that allows small labs performing differentials to streamline patient care; CellaVision Peripheral Blood Application for white blood cell differential, red blood cell characterization, and platelet estimation; CellaVision Advanced RBC Application, which performs pre-characterization of red blood cells; and CellAtlas mobile app. It also offers CellaVision Light Tower that provides visual and audible signals of the status of a CellaVision DM Analyzer; HemaPrep, an automated blood smearing instrument for blood cell analysis; and barcode label printer kit for reading and copying barcodes and generating barcode labels. The company sells its products to hospital and commercial laboratories in Europe, the Middle East, Africa, the Americas, and the Asia Pacific. CellaVision AB (publ) was founded in 1994 and is headquartered in Lund, Sweden.

73 Employees
Last Reported Date: 05/5/15
Founded in 1994

cellavision ab (CEVI) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

cellavision ab (CEVI) Key Developments

CellaVision AB (publ) Approves Dividend for the Year 2014, Payable on May 13, 2015

CellaVision AB (publ) held its Annual General Meeting on May 6, 2015, approved a the payment of dividend in the amount of SEK 1 per share with May 8, 2015 as record date, meaning that payment is expected to be made on May 13, 2015.

CellaVision AB Elects Åsa Hedin as Member of the Board of Directors

CellaVision AB announced that the annual general meeting held on May 6, 2015, approved the election of Åsa Hedin as a new member of the Board of Directors.

CellaVision AB Announces Consolidated and Parent Earnings Results for the First Quarter Ended March 31, 2015

CellaVision AB announced consolidated and parent earnings results for the first quarter ended March 31, 2015. For the quarter, on consolidated basis the company reported net sales of SEK 51.8 million against SEK 43.2 million a year ago. Operating profit was SEK 10.5 million against SEK 7.5 million a year ago. Profit before tax was SEK 10.8 million against SEK 7.4 million a year ago. Profit for the period was SEK 8.11 million against SEK 5.89 million a year ago. Earnings per share were SEK 0.34 against SEK 0.25 a year ago. Cash flow from operations for the quarter was SEK 43.1 million against SEK 29.4 million a year ago. Investments in property, plant and equipment during the quarter amounted to SEK 0.3 million against SEK 0.1 million a year ago. For the quarter, the parent company reported sales were SEK 49.17 million against SEK 41.5 million a year ago. Profit before tax and net profit was SEK 10.3 million against SEK 6.8 million a year ago. The parent company's investments in property, plant and equipment and intangible assets during the quarter amounted to SEK 2.1 million against SEK 3.6 million a year ago and cash flow to SEK 45.4 million against SEK 24.6 million a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CEVI:SS kr44.10 SEK +0.10

CEVI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $49.01 USD -0.96
Siemens AG €91.63 EUR +0.117
Sysmex Corp ¥7,300 JPY +40.00
View Industry Companies
 

Industry Analysis

CEVI

Industry Average

Valuation CEVI Industry Range
Price/Earnings 33.1x
Price/Sales 4.9x
Price/Book 7.0x
Price/Cash Flow 33.1x
TEV/Sales 4.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELLAVISION AB, please visit www.cellavision.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.